share_log

Retail Investors Are Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Biggest Owners and Were Hit After Market Cap Dropped CN¥813m

Retail Investors Are Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Biggest Owners and Were Hit After Market Cap Dropped CN¥813m

散户投资者是恩华药业(深交所代码:002262)最大的股东,在市值下跌了8.13亿人民币后受到影响。
Simply Wall St ·  01/01 07:52

Key Insights

关键洞察

  • Significant control over Jiangsu Nhwa Pharmaceutical by retail investors implies that the general public has more power to influence management and governance-related decisions
  • A total of 6 investors have a majority stake in the company with 51% ownership
  • Insiders own 18% of Jiangsu Nhwa Pharmaceutical
  • 散户对恩华药业的重大控制权意味着公众在管理和治理相关决策上的影响力更大。
  • 共有6位投资者在公司中拥有51%的控股权
  • 内部人士持有恩华药业18%的股份。

A look at the shareholders of Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) can tell us which group is most powerful. With 34% stake, retail investors possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

查看恩华药业有限公司(深圳证券交易所代码:002262)的股东可以告诉我们哪个群体最强大。散户持有34%的股份,是公司中拥有最多股份的群体。换句话说,这个群体从他们对公司的投资中获利最多(或损失最多)。

As market cap fell to CN¥25b last week, retail investors would have faced the highest losses than any other shareholder groups of the company.

由于市值上周跌至250亿人民币,散户投资者所承受的损失比公司的其他股东群体要大得多。

Let's take a closer look to see what the different types of shareholders can tell us about Jiangsu Nhwa Pharmaceutical.

让我们仔细看看不同类型的股东能告诉我们关于恩华药业的哪些信息。

big
SZSE:002262 Ownership Breakdown December 31st 2024
SZSE:002262 股权结构,截至2024年12月31日

What Does The Institutional Ownership Tell Us About Jiangsu Nhwa Pharmaceutical?

机构所有权能够告诉我们关于江苏恩华药业的什么信息?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

许多机构的表现与近似当地市场的指数进行比较。因此,他们通常更加关注那些被纳入主要指数的公司。

As you can see, institutional investors have a fair amount of stake in Jiangsu Nhwa Pharmaceutical. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Jiangsu Nhwa Pharmaceutical, (below). Of course, keep in mind that there are other factors to consider, too.

如你所见,机构投资者在恩华药业中拥有相当的股份。这表明为这些机构工作的分析师已经关注了这只股票,并且他们对其持积极看法。但和其他人一样,他们也可能会错误。如果两家大型机构投资者同时试图抛售股票,股票价格大幅下跌并不罕见。因此,值得查看一下恩华药业过去的盈利轨迹(如下)。当然,还有其他因素也需要考虑。

big
SZSE:002262 Earnings and Revenue Growth December 31st 2024
SZSE:002262 盈利和营业收入增长截至2024年12月31日

Hedge funds don't have many shares in Jiangsu Nhwa Pharmaceutical. Xuzhou Nhwa Investment Co., Ltd. is currently the company's largest shareholder with 32% of shares outstanding. Pengsheng Sun is the second largest shareholder owning 4.9% of common stock, and Zengliang Chen holds about 3.9% of the company stock. Zengliang Chen, who is the third-largest shareholder, also happens to hold the title of Member of the Board of Directors.

对冲基金在恩华药业的股份不多。徐州恩华投资有限公司目前是公司最大的股东,持有32%的流通股。彭胜孙是第二大股东,拥有4.9%的普通股,而曾亮陈持有约3.9%的公司股票。曾亮陈是第三大股东,同时也担任董事会成员。

We did some more digging and found that 6 of the top shareholders account for roughly 51% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

我们进行了更多的挖掘,发现前六大股东大约占股东注册的51%,这意味着除了大股东,还有一些小股东,从而在某种程度上平衡了彼此的利益。

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

虽然研究一家公司的机构持股数据是有意义的,但研究分析师的情绪以了解市场趋势同样也是有意义的。现在有相当多的分析师关注这只股票,因此了解他们对未来的整体看法可能会很有用。

Insider Ownership Of Jiangsu Nhwa Pharmaceutical

江苏恩华药业的内部所有权

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

虽然对内部人的确切定义可能是主观的,但几乎每个人都认为董事会成员是内部人。公司管理层运行业务,但CEO会向董事会报告,即使他或她是董事会成员。

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

当内部持股显示领导层像真正的公司所有者一样思考时,这是积极的。然而,高比例的内部持股也可能给予公司内部小团体巨大的权力。在某些情况下,这可能是负面的。

Our most recent data indicates that insiders own a reasonable proportion of Jiangsu Nhwa Pharmaceutical Co., LTD. Insiders own CN¥4.4b worth of shares in the CN¥25b company. That's quite meaningful. It is good to see this level of investment. You can check here to see if those insiders have been buying recently.

我们最新的数据表明,内部人士持有恩华药业合理比例的股份。内部人士持有价值44亿人民币的股份,在这家市值250亿人民币的公司中。这是相当有意义的。看到这种投资水平真是令人高兴。您可以在这里查看这些内部人士最近是否有买入。

General Public Ownership

公众持股

With a 34% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Jiangsu Nhwa Pharmaceutical. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

公众持有34%的股份,主要由个人投资者组成,他们对恩华药业有一定的影响力。虽然这种持股规模可能不足以影响政策决策,但他们仍然可以对公司政策产生集体影响。

Private Company Ownership

私有公司所有权

We can see that Private Companies own 32%, of the shares on issue. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

我们可以看到,私人公司拥有32%的发行股份。值得进一步深入了解一下。如果相关方,例如内部人士,对这些私人公司之一有利益关系,那么应在年度报告中披露。私人公司也可能对该公司有战略利益。

Next Steps:

下一步:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too.

我觉得研究到底是谁拥有一家公司非常有趣。但要真正获得洞察,我们还需要考虑其他信息。

Many find it useful to take an in depth look at how a company has performed in the past. You can access this detailed graph of past earnings, revenue and cash flow.

许多人发现深入分析公司过去的表现很有用。您可以访问这一详细的历史营业收入、营业收入和现金流的图表。

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

如果您想了解分析师对未来增长的预测,请不要错过这份关于分析师预测的免费报告。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的数字是根据过去十二个月的数据计算得出的,指的是截至财务报表日期的月份最后一天的12个月期间。这可能与完整年度的年报数字不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有反馈?对内容有疑虑?请直接与我们联系。或者,发送电子邮件至 editorial-team (at) simplywallst.com。
这篇来自Simply Wall St的文章是一般性的。我们根据历史数据和分析师预测提供评论,采用无偏见的方法,我们的文章并不旨在提供财务建议。它不构成对任何股票的买入或卖出建议,也未考虑到您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均没有持仓。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发